Latest news with #SGLT2inhibitors
Medscape
16 hours ago
- Health
- Medscape
SGLT2 Inhibitors Linked to Lower Risk for AF in T2D
The use of SGLT2 inhibitors was associated with a reduced risk for atrial fibrillation (AF) in patients with type 2 diabetes (T2D). METHODOLOGY: SGLT2 inhibitors have been shown to provide therapeutic benefits to patients with heart failure and AF; however, data on their protective effect on AF in patients without heart failure are inconsistent. Researchers conducted a retrospective case-control study in Germany to assess the association between the use of various antihyperglycemic medications between 2005 and 2023 and the diagnosis of AF in patients with T2D during the same period. They used data from the Disease Analyzer database including 29,424 patients with T2D aged 40 years or older with an initial diagnosis of AF who were matched to an equal number of control patients without AF (mean age at the index date , 76 years; 46%-47% women; average diabetes duration prior to the index date for both cohorts, 6.8 years). Antihyperglycemic therapies included metformin, sulfonylurea, GLP-1 receptor agonists (RAs), DPP-4 inhibitors, SGLT2 inhibitors, and insulin. TAKEAWAY: Treatment with SGLT2 inhibitors was associated with a reduced risk for AF (odds ratio [OR], 0.82; P < .01 per year of therapy). < .01 per year of therapy). GLP-1 RAs were associated with a slightly reduced risk for AF (OR, 0.93; P < .01), with a stronger association among women (OR, 0.89), patients aged 71-80 years (OR, 0.88), and patients older than 80 years (OR, 0.81; P < .01 for all). < .01), with a stronger association among women (OR, 0.89), patients aged 71-80 years (OR, 0.88), and patients older than 80 years (OR, 0.81; < .01 for all). The use of sulfonylurea was linked to a slightly increased risk for AF (OR, 1.09; P < .01), with the strongest association among patients younger than 70 years (OR, 1.18; P < .01). < .01), with the strongest association among patients younger than 70 years (OR, 1.18; < .01). Patients with AF began SGLT2 inhibitor therapy on average 2.6 years before diagnosis, with the therapy lasting an average of 2.3 years. IN PRACTICE: 'SGLT2i [inhibitors] and GLP-1 RA may provide an important, heretofore unknown effect of antidiabetic therapy: The prevention of AF, a cardiac condition of massive prevalence and severe impact for those affected,' the authors wrote. SOURCE: This study was led by Mark Luedde, MD, and Jamschid Sedighi, MD, of the University Hospital of Giessen and Marburg, Giessen, Germany. It was published online on June 03, 2025, in Diabetes, Obesity and Metabolism . LIMITATIONS: This study lacked data on the frequency and duration of AF episodes. The absence of data on cardiovascular disease severity may have affected the balance between groups. Potential bias due to the indication of oral antidiabetic treatments cannot be ruled out. DISCLOSURES: This study did not report any specific funding. The authors reported having no relevant conflicts of interest.
Yahoo
27-05-2025
- Business
- Yahoo
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat Newly granted U.S. patent expected to provide exclusivity through 2044 with subsequent opportunity for patent term extension New U.S. patent granted after accelerated examination process covers the active polymorph of varoglutamstat, Vivoryon's lead drug in development Additional patents for medical use and dosing regimens under examination for varoglutamstat and related structures in kidney disease as monotherapy and in combination with SGLT-2 inhibitors Halle (Saale) / Munich, Germany, May 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent covering the Company's lead drug in development, varoglutamstat. The new patent was granted after an accelerated examination process. 'Vivoryon pursues a diligent and comprehensive strategy to continuously strengthen the intellectual property protecting our key assets on multiple levels. This successful patent application demonstrates our strong commitment to protecting the innovation of our lead asset varoglutamstat and is an important milestone for Vivoryon. The fact that it has been granted several months ahead of the anticipated timing is a testament to the outstanding work of our team,' said Frank Weber, MD, CEO of Vivoryon. 'We expect that this long patent runway will support our efforts to maximize the full therapeutic potential of varoglutamstat, which we plan to develop in kidney disease.' The newly granted composition of matter US patent (US 12,312,335) covers the only polymorph of the salt form used in the drug product of Vivoryon's unique QPCT/L inhibitor varoglutamstat. The patent has a scheduled runtime through 2044, with the subsequent opportunity for a patent term extension of up to five years to 2049 under the Hatch-Waxman Act. In addition, the Company has filed a number of different patents in its focus area of kidney disease over the past months. These relate to varoglutamstat and related structures, covering medical use, and dosing regimens, both as monotherapy and in combination with standard of care, namely SGLT-2 inhibitors. Adding an additional layer of protection, the patent applications cover the free base and all salt forms of varoglutamstat and are currently under examination. Vivoryon has a strong patent portfolio for QPTC/L inhibition and continues to evolve its IP strategy based on scientific evidence, striving to bolster its IP portfolio on multiple levels. Patent applications and granted patents span composition of matter, medical use as well as indications and dosing regimens. Recent additions to the portfolio relate to the Company's primary field of focus, diseases of the kidney and include patents for the combination of QPCT/L inhibitors with standard of care, SGLT-2 inhibitors. These patents were filed based on the outstanding effect observed in preclinical research, where data revealed synergistic effect of the combination treatment with varoglutamstat and an SGLT-2 inhibitor with both once and twice daily treatment. The Company has a strong patent portfolio relating to QPCT/L inhibitors in a broad range of diseases with high medical need, including kidney diseases, inflammatory diseases, oncology, genetic and fibrotic diseases. The portfolio is comprised of over 20 patent families and over 400 patent applications and issued patents covering all major markets, with composition of matter patents on QPCT/L inhibitors representing the clear majority and with recent patent applications reflecting Vivoryon's focus on kidney diseases. ### About Vivoryon Therapeutics is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer's disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the 'Company'), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'plan,' 'project,' 'predict,' 'should' and 'will' and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor ContactsVivoryon Therapeutics Manuela Bader, Director IR & CommunicationEmail: IR@ LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38Email: svonderweid@ Media ContactTrophic CommunicationsValeria Fisher or Verena SchossmannTel: +49 175 8041816 / +49 151 219 412 77Email: vivoryon@ Attachment 250527_VVY US Patent Press Release_FINError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
13-05-2025
- Health
- Medscape
Preoperative SGLT2 Use Linked to Lower AKI Risk Post-Surgery
Preoperative use of sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced the risk for acute kidney injury (AKI) by 31% after surgery, according to this retrospective, case-control study. METHODOLOGY: Case reports and small retrospective studies have suggested an increased risk for postoperative euglycemic ketoacidosis and AKI in patients using SGLT2 inhibitors preoperatively; however, the actual risks for these conditions are not well understood. Researchers conducted a retrospective case-control study using data from the Veterans Affairs Health Care System National Registry (2014-2022) to evaluate risks for postoperative euglycemic ketoacidosis, AKI, and mortality within 30 days after surgery in 7439 preoperative SGLT2 inhibitor users (mean age, 67.7 years; 96.7% men) and 33,489 propensity-matched nonusers (mean age, 67.9 years; 96.4% men). Long-term use of preoperative SGLT2 inhibitors was defined as having three or more fills of outpatient prescription within 3 months prior to surgery or less than a 180-day gap since the most recent fill according to pharmacy registries. The duration of SGLT2 inhibitor suspension prior to the surgical procedures was not available for this cohort. The primary outcome was postoperative euglycemic ketoacidosis; secondary outcomes were postoperative AKI and 30-day in-hospital mortality. TAKEAWAY: Preoperative SGLT2 inhibitor users had reduced risks for AKI (odds ratio [OR], 0.69; 95% CI, 0.62-0.78) and 30-day mortality (OR, 0.70; 95% CI, 0.55-0.88) after surgery but had a modestly increased risk for postoperative euglycemic ketoacidosis (OR, 1.11; 95% CI, 1.05-1.17). The renal protective effects of SGLT2 inhibitors were not seen in patients who underwent cardiac surgery or emergency procedures but were observed in those who underwent noncardiac surgery (OR, 0.63; 95% CI, 0.56-0.71) and nonemergency procedures (OR, 0.64; 95% CI, 0.56-0.72). The increased risk for postoperative euglycemic ketoacidosis among SGLT2 inhibitor users was most prominent in those who underwent cardiac surgery (OR, 1.30; 95% CI, 1.11-1.54), whereas the greatest mortality benefits were observed in patients who underwent emergency surgery (OR, 0.49; 95% CI, 0.26-0.93). IN PRACTICE: 'Renoprotective effects of SGLT2i [SGLT2 inhibitor] in the perioperative setting could have far-reaching implications given the annual volume of patients undergoing surgical procedures and the burden of postoperative AKI,' the authors concluded. SOURCE: This study was led by Roberta Teixeira Tallarico, MD, Department of Anesthesia and Perioperative Care, University of California San Francisco. It was published online in JAMA Surgery . LIMITATIONS: The observational nature of this study limited the ability to establish direct causality. The exact timing of the last SGLT2 inhibitor administration before surgery was unknown, and the absence of ketone measurements limited their diagnostic criteria for euglycemic ketoacidosis. The study population primarily consisted of White male veterans older than 60 years, which limited the generalizability of the results. DISCLOSURES: This study was supported by the National Institute of General Medical Sciences of the National Institutes of Health, the statistical core of the University of California San Francisco ( UCSF) Pepper Center through the National Institutes of Health, the UCSF FAST-CaR Seed Research Grant, and UCSF Anesthesia Research. Some authors reported receiving grants and personal fees from and having other ties with certain institutions and pharmaceutical companies including the funding sources.
